Theravance settles YUPELRI patent litigation with Cipla; generic launch date April 23, 2039

Theravance Biopharma, Inc.

Settlement resolves Hatch-Waxman patent litigation on YUPELRI (revefenacin) inhalation solution.
Cipla granted royalty-free license to market generic version in U.S. on or after April 23, 2039.
Settlement subject to review by U.S. DOJ and FTC as required by law.
Patent litigation remains pending against Mankind Pharma Ltd. and affiliates (another ANDA filer).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.